Bb Biotech Ag Acquired Stake in Intra-Cellular Therapies, Inc

February 15, 2018 - By Michael Collier

 Bb Biotech Ag Acquired Stake in Intra Cellular Therapies, Inc

Investors sentiment increased to 2.77 in Q3 2017. Its up 1.91, from 0.86 in 2017Q2. It is positive, as 9 investors sold Intra-Cellular Therapies, Inc. shares while 21 reduced holdings. 45 funds opened positions while 38 raised stakes. 39.74 million shares or 30.25% more from 30.51 million shares in 2017Q2 were reported.

Gp One Trading Ltd Partnership holds 0.01% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) or 38,086 shares. Geode Cap Management Ltd Liability owns 337,189 shares for 0% of their portfolio. Vanguard Gp accumulated 3.47M shares. Dimensional Fund L P invested 0.01% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Credit Suisse Ag reported 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Bancorp Of Montreal Can reported 0% stake. Bank & Trust Of America De, North Carolina-based fund reported 805,834 shares. Clough Cap Lp has 0.7% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Northern stated it has 403,825 shares or 0% of all its holdings. 187,500 were reported by Rock Springs Mgmt L P. Art Advsr Ltd accumulated 0.11% or 141,157 shares. Retail Bank Of New York Mellon holds 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 169,129 shares. Moreover, Jane Street Gp Limited Liability has 0% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 39,780 shares. Parametric Portfolio Assoc Ltd Limited Liability Company has invested 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Moreover, Swiss Bancorp has 0% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 69,800 shares.

Since September 29, 2017, it had 3 insider purchases, and 9 insider sales for $10.92 million activity. 6,604 shares were sold by Mates Sharon, worth $115,438. 1,115 shares were sold by Davis Robert E, worth $17,394 on Wednesday, January 3. Shares for $82,725 were sold by Hineline Lawrence J.. 7,000 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) shares with value of $105,630 were sold by LERNER RICHARD A. On Monday, October 2 the insider ALAFI CAPITAL CO LLC bought $4.00M. Vanover Kimberly E. had sold 772 shares worth $13,479.

The New Bb Biotech Ag Holding in Intra-Cellular Therapies, Inc

Bb Biotech Ag reported SC 13G/A form with the SEC for Intra-Cellular Therapies, Inc. Access it here: 000119312518045457. As reported by Bb Biotech Ag, the filler owns 4.0% or 2,200,000 shares of the Health Care–company.

Intra-Cellular Therapies, Inc stake is new for [reportingPerson]. Date of activity: December 31, 2017. This shows Bb Biotech Ag’s positive view for Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc Institutional Sentiment

Filings show 123 investors own Intra-Cellular Therapies, Inc. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 9906396. 27688666 were owned by these investors. 44 funds opened new Intra-Cellular Therapies, Inc stakes, 45 increased positions. There were 10 that closed positions and 26 reduced them.

2 investors had the stock in their top 10. Some are: .

Alex Denner Sarissa Capital Management Lp is an investor bullish on Intra-Cellular Therapies, Inc, owning 640000 shares as of Q3 2015 for 6.33% of its portfolio. Wall Street Associates owns 205657 shares or 1.58% of its portfolio. NC Franklin Street Advisors Inc have 0.26% of its portfolio for 33200 shares. Further, Hodges Capital Management Inc reported stake worth 0.07% of its portfolio. The A8 Fiera Capital Corp owns 18320 shares. Intra-Cellular Therapies, Inc is 0.01% of its portfolio.

Business Profile

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company is discovering and developing drugs for the treatment of neurological and psychiatric disorders. Lumateperone (also known as ITI-007) is its lead product candidate. The Company’s bipolar depression program consists of two Phase III multi-center, randomized, double-blind, placebo-controlled clinical trials: one to evaluate lumateperone as a monotherapy and the other to evaluate lumateperone as an adjunctive therapy with lithium or valproate. The Company initiated Phase III development of lumateperone for the treatment of agitation in patients with dementia, including Alzheimer’s Disease (AD).

SEC Form 13G.

Analysts await Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) to report earnings on March, 7. They expect $-0.51 earnings per share, up 20.31 % or $0.13 from last year’s $-0.64 per share. After $-0.53 actual earnings per share reported by Intra-Cellular Therapies, Inc. for the previous quarter, Wall Street now forecasts -3.77 % EPS growth.

The stock increased 4.17% or $0.8 during the last trading session, reaching $19.99. About 530,424 shares traded or 21.63% up from the average. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has declined 68.76% since February 15, 2017 and is downtrending. It has underperformed by 85.46% the S&P500.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The company has market cap of $1.09 billion. The firm is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. It currently has negative earnings. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Ratings Coverage

Among 11 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 10 have Buy rating, 0 Sell and 1 Hold. Therefore 91% are positive. Intra-Cellular Therapies has $104 highest and $1000 lowest target. $54.10’s average target is 170.64% above currents $19.99 stock price. Intra-Cellular Therapies had 36 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Buy” rating by SunTrust given on Wednesday, November 8. Piper Jaffray upgraded the stock to “Buy” rating in Thursday, September 7 report. The firm has “Overweight” rating given on Thursday, June 2 by Piper Jaffray. The stock of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) earned “Buy” rating by Cowen & Co on Wednesday, August 9. The firm has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The rating was maintained by Cowen & Co with “Buy” on Wednesday, August 23. The stock of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has “Neutral” rating given on Thursday, September 29 by SunTrust. As per Thursday, September 17, the company rating was maintained by Guggenheim. The stock of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has “Outperform” rating given on Friday, November 6 by RBC Capital Markets. Cowen & Co maintained it with “Buy” rating and $27.0 target in Friday, September 8 report.

More notable recent Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) news were published by: which released: “Intra-Cellular Therapies to Present at the 36th Annual JP Morgan Healthcare …” on January 02, 2018, also with their article: “Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone …” published on November 20, 2017, published: “Why Intra-Cellular Therapies Is Plunging” on May 01, 2017. More interesting news about Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) were released by: and their article: “Intra-Cellular Therapies to Present at Upcoming Investor Conferences” published on February 07, 2018 as well as‘s news article titled: “Intra-Cellular Therapies Reports Third Quarter 2017 Financial Results and …” with publication date: November 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: